January 2, 2020
Astellas & Pfizer's Enzalutamide Receives FDA-Approval for Treatment of Metastatic Castration-Sensitive Prostate Cancer
On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). FDA previously approved enzalutamide for patients with castration-resistant prostate cancer. Efficacy was investigated in ARCHES (NCT02677896), a trial enrolling 1150 patients with mCSPC randomized (1:1) to receive either enzalutamide orally 160 mg once...
Study Suggests BMI Affects Multiple Sclerosis Disease Progression
A recent study suggests that there may be a link between MS progression and blood lipids in MS patients who are overweight or obese. The study published in the Lancet journal EBioMedicine supports previous research that hints food, diet, and exercise can help affect disease progression in MS patients. The study was conducted by researchers at the...